Enliven Therapeutics
NASDAQ · ELVN·Boulder, CO·Small-cap·Phase 3
Clinical-stage oncology biotech developing kinase inhibitors. Lead asset ELVN-001 is a selective BCR-ABL inhibitor in pivotal Phase 3 for chronic myeloid leukemia. ELVN-002 is an irreversible HER2 inhibitor in Phase 1 for HER2+ solid tumors.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Enliven Non-Confidential Overview JPM 2026 | JPM Healthcare | January 13, 2026 | 51 |